Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Everest Medicines's Enterprise Value is HK$6,603 Mil.
Everest Medicines's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-633 Mil. Therefore, Everest Medicines's EV-to-EBIT ratio for today is -10.44.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Everest Medicines's Enterprise Value is HK$6,603 Mil.
Everest Medicines's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-461 Mil. Therefore, Everest Medicines's EV-to-EBITDA ratio for today is -14.34.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Everest Medicines's Enterprise Value is HK$6,603 Mil.
Everest Medicines's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was HK$1,880 Mil. Therefore, Everest Medicines's EV-to-Revenue ratio for today is 3.51.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Everest Medicines (HKSE:01952) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Everest Medicines's current Enterprise Value is HK$6,603 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Everest Medicines's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-633 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Everest Medicines's current Enterprise Value is HK$6,603 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Everest Medicines's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-461 Mil.
Everest Medicines's current Enterprise Value is HK$6,603 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Everest Medicines's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was HK$1,880 Mil.
Everest Medicines's current Enterprise Value is HK$6,603 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Everest Medicines's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-100 Mil.
Everest Medicines's current Enterprise Value is HK$6,603 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Everest Medicines's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-484 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Everest Medicines Enterprise Value Related Terms
Everest Medicines Enterprise Value Historical Data
* Premium members only.
The historical data trend for Everest Medicines's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:01952 vs VRTX, REGN, ALNY: Enterprise Value Comparison
For the Biotechnology subindustry, Everest Medicines's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Everest Medicines Enterprise Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Everest Medicines's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Everest Medicines's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Everest Medicines's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of HK$6,603 Mil mean?
Everest Medicines (HKSE:01952) has a Enterprise Value of HK$6,603 Mil as of Jul. 18, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Everest Medicines and its competitors.
Is Everest Medicines' Enterprise Value too high?
Everest Medicines' current Enterprise Value is HK$6,603 Mil. Overall, Everest Medicines has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Everest Medicines' Enterprise Value compare to VRTX and REGN?
Everest Medicines' Enterprise Value of HK$6,603 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Biotechnology company?
A good Enterprise Value depends on the Biotechnology industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Everest Medicines and its competitors. Everest Medicines's current Enterprise Value is HK$6,603 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Everest Medicines stock overvalued right now?
Based on GuruFocus' analysis, Everest Medicines (HKSE:01952) is currently considered Possible Value Trap. The stock's GF Value™ is HK$297.88, compared to a current price of HK$24.72 — trading 91.7% below its estimated fair value. The current Enterprise Value is HK$6,603 Mil. Everest Medicines' overall GF Score™ is 42/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Everest Medicines (HKSE:01952), the current Enterprise Value is HK$6,603 Mil as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Everest Medicines (HKSE:01952) Overvalued in 2026?
Based on GuruFocus' analysis, Everest Medicines stock appears to be undervalued.
The current stock price of HK$24.72 is trading 91.7% below its estimated GF Value™ of HK$297.88.
GuruFocus considers Everest Medicines to be Possible Value Trap.
Key valuation signals for HKSE:01952:
Enterprise Value: HK$6,603 Mil
GF Value™: HK$297.88 vs. price of HK$24.72 (91.7% below fair value)
No single metric tells the full story. See the HKSE:01952 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Everest Medicines Ltd is a biopharmaceutical company that integrates discovery, licensing, clinical development, commercialization, and manufacturing of potentially novel or differentiated therapies and vaccines to address critical unmet medical needs initially in the Asia Pacific markets and eventually around the world. Its product pipeline includes: Nefecon (TarpeyoTM), EVER001, Eravacycline (Xerava), SPR206, and others. Geographically operates in Mainland China.
42GF Score
Get the complete analysis for HKSE:01952
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01952 has been successfully added to your 
